JonesResearch downgraded Theratechnologies (THTX) to Hold from Buy after the company announced an agreement with CB Biotechnology, an affiliate of Future Pak, to be acquired for $3.01 per share in cash plus one contingent value right per share for additional aggregate cash payments of up to $1.19 per CVR if certain milestones are achieved.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THTX: